Recently, it has been shown that administration of gliflozins—sodium-glucose transporter type 2 (SGLT2) inhibitors—to patients with type 2 diabetes mellitus induces persistent osmotic diuresis, which in turn promotes the release of AVP (evaluated by plasma copeptin levels), which by its antidiuretic activity counteracts osmotic diuresis-induced dehydration [234]. Here, AVP is linked to type 2 diabetes mellitus.